Dermovate cream in Orabase

Phase 1Protein / enzyme

BBeni-Suef University

Dermovate cream in Orabase is one of 14 small molecule programs targeting Oral ulcer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral UlcerActive, not recruiting

Oral UlcerPhase 1

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Oral Ulcer

#DrugCompanyPhaseTrials

Otezla

Amgen

Phase 3

1 2

Carafate

AbbVie

Phase 2

1 3

Colcrys

Alnylam Pharmaceuticals

Phase 2

1 4

Mesalazine

Ferring

Phase 3

1 5

Advil

KKenvue Brands

Phase 2

1 6

Trental

VValidus Pharmaceuticals

Phase 2

1 7

Tylenol

KKenvue Brands

Phase 2

1 8

Folvite

Eli Lilly

Phase 1

1 9

Curcumin

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oral ulcer1 trial

PRF in Management of Chronic Multiple Oral Ulcers

Completed·—·Phase 1·NCT03878771·804 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dermovate cream in Orabase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dermovate cream in Orabase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dermovate cream in Orabase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beni-Suef University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 1[1]
Company: BBeni-Suef University

Dermovate cream in Orabase

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oral ulcer1 trial

References

Drug Info

Quick Facts

Related News